(1) Journal Source
Progress in Retinal and Eye Research（2026年，IF 16.2）

(2) Title
Original title: Novel insights into retinoblastoma: From oncogenic circuitry to precision diagnosis and eye-preserving therapies.

(3) Research Approach
The review starts from the classic RB1/pRB–E2F pathway and extends to MYCN-driven pathogenesis, epigenetic and RNA modifications, chromosomal abnormalities, cone precursor cell origin, and intratumoral heterogeneity. It summarizes IIRC, ICRB, and AJCC TNMH staging and risk stratification; integrates imaging and aqueous humor liquid biopsy cfDNA/ctDNA molecular diagnosis; and reviews focal therapy, intravenous/intra-arterial/intravitreal chemotherapy, surgery, and emerging targeted, gene, and immune strategies.

(4) Innovation
It systematically integrates non-classical oncogenic circuitry, epitranscriptomic regulation, liquid biopsy-based molecular stratification, and eye-preserving therapy; emphasizes a shift from anatomical imaging to molecular diagnosis and from single treatment to risk-adapted multimodal management; discusses MYCN and other alternative drivers and the cavitary RB phenotype; and summarizes potential targets including AURKA, HDAC, SYK, RNA methylation, rAAV2-RB1, and CAR-T.

(5) Material Development
This is a review; no new materials, nanocarriers, or delivery systems were developed or characterized. The discussed interventions mainly include therapeutic agents, viral vectors, and cell therapies, without material synthesis, carrier construction, or material-performance evaluation.

We provide full-process services for various material designs (including highly innovative scheme design, preparation, characterization, in vitro and in vivo validation (cell/animal experiments), etc.): a postdoctoral team (with multiple high-impact publications in Zone 1 journals) can meet all kinds of tricky and challenging requirements, including hydrogels / drug delivery / nanomaterials / polymers / liposomes / microneedle drug delivery, etc. We can assist with project design / NSFC grant applications / publication of high-impact Zone 1 and Zone 2 papers in journals such as AFM, SCI, AM, etc. Welcome to consult 👇️
17768014569 (Senior Engineer Gao)
17761925168 (Engineer Zhang)
18013729810 (Engineer Yang)

#Retinoblastoma #RB1 #MYCN #LiquidBiopsy #EyePreservingTherapy #Oncology #NanoDrugs #NanomaterialCustomization #ResearchServices #SciTalk #ResearchMaterials #BKNano